Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinshukang Tablets
- Development stage
- Phase 2
- Lead developer
- Hebei
- Administration
- Oral
01
Overview
Xinshukang Tablets is a Traditional Chinese Medicine (TCM) developed by Tangshan Longshan Pharmaceutical for the treatment of cardiovascular conditions. It is specifically indicated for patients with coronary artery disease and angina pectoris who exhibit the TCM pattern of 'Qi deficiency and blood stasis.' The formulation is designed to tonify Qi and promote blood circulation to resolve stasis, thereby improving myocardial blood supply and reducing the frequency and severity of angina episodes. It has been evaluated in Phase 2 clinical trials in China to assess its efficacy and safety as a therapeutic intervention for stable angina.
- Brand names
- Xinshukang Tablets
- Other names
- Xinshukang Pian
Beyond the preview
Go deeper on Xinshukang Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xinshukang Tablets.